Acknowledgements
Cost of Illness: An Ongoing Battle Worth Fighting
“Can We Declare Victory and Move On?” The Case Against Funding Burden-of-Disease Studies
A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials
Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
A Review of the Methodological Challenges in Assessing the Cost Effectiveness of Pharmacist Interventions
A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments
The Humanistic Burden of Head and Neck Cancer: A Systematic Literature Review
Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer
Comment on: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”
Authors' Reply to Gandjour: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”
Objectivity and Equity: Clarity Required. A Response to Hill and Olson